[Perinatal corticotherapy: updates]. / La corticothérapie périnatale: actualités.

ABSTRACT

The beneficial effects of antenatal corticosteroid treatment are now well established. Likewise, a functional pulmonary improvement has been demonstrated when corticosteroids are used in neonates with chronic lung disease. However, several questions remain to be answered. This review of recent data suggest the need for an updated policy of treatment to improve prognosis. In our population, antenatal maturation has reached a level of 77% below 32 weeks gestation and is associated with a 50% reduction of the risk of severe respiratory distress syndrome. Antenatal steroids have been shown to be beneficial as soon as 23 weeks gestation, but the indication for treatment needs to be carefully evaluated since side effects appear to overcome benefits above 3 repeated courses of treatment. An optimal interval between each course can be set at 10 to 15 days according to the severity of premature labor and gestational age. Since several experimental and clinical studies suggest an increased risk of neurological disability with dexamethasone as compared with betamethasone, it seems consistent to favor the exclusive use of antenatal betamethasone as well as its postnatal choice when indicated. Postnatal use should be restricted to severe chronic lung disease and pulse therapy is now the optimal choice to reduce side effects.